Dakshidin CEO Joins GenBio CEO on Podcast to Discuss Entering 191 Billion Dollar Anti-Inflammatory Market, Their Strategic Partnership and Research Potential
Dakshidin Corp (DKSC) announced a strategic partnership with GenBio Inc, focusing on developing anti-inflammatory drugs derived from natural extracts. CEO Chris Haigh noted that the collaboration, which aligns with their rebranding to Whitechapel Holdings, aims to leverage unique products addressing health issues post-pandemic. GenBio's research has identified promising extracts and mechanisms of action, potentially leading to a groundbreaking Investigational New Drug program in the U.S. This initiative targets the expanding health and wellness market, expected to impact sales significantly in the coming quarters.
- Strategic partnership with GenBio aimed at developing innovative anti-inflammatory drugs.
- Focus on natural extracts aligns with increasing market demand for health and wellness products.
- New drug program entering Investigational New Drug stage may enhance market positioning.
- None.
SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Dakshidin Corp (OTC PINK:DKSC) CEO Chris Haigh and Giles Tilley, Managing Director of GenBio Inc. an early-stage Biotechnology Company joined Stock Day host Everett Jolly for an interview.
"How did you get involved with GenBio?", Jolly asked Haigh. "It was prior to the epidemic to start with," explained Haigh. "I was introduced to Giles by a mutual acquaintance who thought that there was a synergy between us," he continued, noting that Dakshidin is in the process of being renamed 'Whitechapel Holdings'. "Whitechapel is very involved, and has been for a long time, in the health and wellness space, but completely organic and natural," said Haigh.
"We've looked at a number of different approaches to what we felt, based upon market research, were the significant issues and complaints where products should be designed and aimed at," continued Haigh. "Giles is an absolute authority on natural products, the science behind them, and how to be able to refine the extracts from those products," he shared. "When Giles and I first met it became obvious to both of us that there was a tremendous synergy there."
"Who is GenBio and what is your mission?", Jolly asked Tilley. "We are primarily a US-based biotech research company and our mission is to develop the next generation of anti-inflammatory drugs," said Tilley. "In Australia, there are natural extracts that demonstrate outstanding potential in the medical and health field," he added, noting that GenBio has studied around 300 extracts over the last five years. "We have whittled it down to about five, which we believe merits research," continued Tilley. "Out of those five, probably two or three are undergoing research in the USA," he shared. "We have identified new mechanisms of action, which gives us leverage in the marketplace."
Tilley then shared that these extracts also have the potential to be added to CBD formulations.
"What is your company's unique selling point?", asked Jolly. "The unique selling point of our company is that we currently have a research program with an entirely new mechanism of action, an entirely new platform, and a more powerful anti-inflammatory drug program with, we believe, lower toxicity than existing pharmaceutical drugs," shared Tilley. "That is about to enter an Investigational New Drug program in the United States, as we speak."
Jolly then asked about the potential of the synergy between these two companies. "The health and wellness space, following the pandemic, is now a much larger space where customers are much more interested in their personal health, as well as the education behind that," said Haigh. "Having the science supplied by GenBio and having unique products that are aimed specifically at these viral issues, we believe, will give us the edge in that market."
"You believe this is going to dovetail into your company's sales and operations, and will hit your bottom line in the next two to four quarters?", asked Jolly. "Significantly," responded Haigh.
To close the interview, Tilley and Haigh expressed confidence in the potential of their partnership to develop the next generation of anti-inflammatory drugs as the health and wellness industry continues to transform. "What we hope for is a line of absolutely organic and natural products that are effective and will truly help with health issues without the use of pharmaceuticals," closed Haigh.
To hear the entire interview with Giles Tilley and Chris Haigh, follow the link to the podcast here: https://audioboom.com/posts/7866978-genbio-inc-discusses-entering-the-191-billion-dollar-anti-inflammatory-market-potential-of-the.
GenBio Inc. is an early-stage Biotechnology Company with unrivaled (and possibly unique) research expertise based on an unexpected yet vitally important medical research breakthrough - described by the US scientific team as "never seen before".
Company Contact Information
IR: + 1 949 716-6030
General inquiries: genbioinc@gmail.com
Investor Inquiries: trilogyir@gmail.com
Company Website, Social Media Outlets, and Crowdfunding Opportunity
GenBio Inc., Twitter, Facebook, LinkedIn
GenBio Opportunity
https://us.trucrowd.com/equity/offer-summary/GenBio
About Dakshidin Corporation (DKSC) and Whitechapel Holdings
DKSC has positioned itself as an innovator and industry leader in the quickly emerging organic health and wellness industry.
Dakshidin Corporation - Investor Relations
Toll free: 1-800-986-6418
Email: dksc.corp@gmail.com
Twitter: https://twitter.com/whitechapelusa
Forward looking statements
The information in this press release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
SOURCE: Dakshidin Corp.
View source version on accesswire.com:
https://www.accesswire.com/648211/Dakshidin-CEO-Joins-GenBio-CEO-on-Podcast-to-Discuss-Entering-191-Billion-Dollar-Anti-Inflammatory-Market-Their-Strategic-Partnership-and-Research-Potential
FAQ
What is Dakshidin Corp (DKSC) planning with GenBio?
What impact will the partnership between DKSC and GenBio have on sales?
What is the unique selling point of GenBio's drug research?
When is the new drug program from DKSC set to enter clinical trials?
